Neuland Laboratories Limited

BSE:524558 Stock Report

Market Cap: ₹192.8b

Neuland Laboratories Valuation

Is 524558 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 524558 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 524558 (₹15024.85) is trading above our estimate of fair value (₹7361.52)

Significantly Below Fair Value: 524558 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 524558?

Key metric: As 524558 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 524558. This is calculated by dividing 524558's market cap by their current earnings.
What is 524558's PE Ratio?
PE Ratio68.9x
Earnings₹2.80b
Market Cap₹192.77b

Price to Earnings Ratio vs Peers

How does 524558's PE Ratio compare to its peers?

The above table shows the PE ratio for 524558 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average41.8x
ERIS Eris Lifesciences
52.9x30.7%₹184.2b
APLLTD Alembic Pharmaceuticals
31.1x21.5%₹201.4b
506943 J. B. Chemicals & Pharmaceuticals
42.7x19.4%₹260.8b
MARKSANS Marksans Pharma
40.4x22.3%₹140.2b
524558 Neuland Laboratories
68.9x33.9%₹192.8b

Price-To-Earnings vs Peers: 524558 is expensive based on its Price-To-Earnings Ratio (68.9x) compared to the peer average (41.8x).

Price to Earnings Ratio vs Industry

How does 524558's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
INDSWFTLAB Ind-Swift Laboratories
1.6xn/aUS$72.79m
524652 Ind-Swift
2xn/aUS$13.15m
No more companies available in this PE range
524558 68.9xIndustry Avg. 32.7xNo. of Companies18PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 524558 is expensive based on its Price-To-Earnings Ratio (68.9x) compared to the Indian Pharmaceuticals industry average (32.7x).

Price to Earnings Ratio vs Fair Ratio

What is 524558's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

524558 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio68.9x
Fair PE Ratio51.7x

Price-To-Earnings vs Fair Ratio: 524558 is expensive based on its Price-To-Earnings Ratio (68.9x) compared to the estimated Fair Price-To-Earnings Ratio (51.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 524558 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹15,024.85
₹17,625.00
+17.3%
13.5%₹20,000.00₹15,250.00n/a2
Nov ’25₹14,542.75
₹16,875.00
+16.0%
18.5%₹20,000.00₹13,750.00n/a2
Oct ’25₹12,530.95
₹12,337.50
-1.5%
5.2%₹12,975.00₹11,700.00n/a2
Sep ’25₹12,520.50
₹11,550.00
-7.8%
1.3%₹11,700.00₹11,400.00n/a2
Aug ’25₹9,373.10
₹9,450.00
+0.8%
20.6%₹11,400.00₹7,500.00n/a2
Jul ’25₹7,725.00
₹8,300.00
+7.4%
9.6%₹9,100.00₹7,500.00n/a2
Jun ’25₹6,040.20
₹8,300.00
+37.4%
9.6%₹9,100.00₹7,500.00n/a2
May ’25₹7,600.75
₹8,300.00
+9.2%
9.6%₹9,100.00₹7,500.00n/a2
Aug ’24₹3,484.25
₹2,505.00
-28.1%
37.7%₹3,450.00₹1,560.00₹9,373.102
Jul ’24₹2,830.65
₹2,505.00
-11.5%
37.7%₹3,450.00₹1,560.00₹7,725.002
Jun ’24₹2,736.35
₹2,280.00
-16.7%
31.6%₹3,000.00₹1,560.00₹6,040.202
May ’24₹2,136.95
₹1,830.00
-14.4%
14.8%₹2,100.00₹1,560.00₹7,600.752
Apr ’24₹1,799.45
₹1,830.00
+1.7%
14.8%₹2,100.00₹1,560.00₹6,267.152
Mar ’24₹1,582.10
₹1,830.00
+15.7%
14.8%₹2,100.00₹1,560.00₹7,271.852
Feb ’24₹1,430.70
₹1,786.00
+24.8%
17.6%₹2,100.00₹1,472.00₹6,231.802
Jan ’24₹1,668.50
₹1,786.00
+7.0%
17.6%₹2,100.00₹1,472.00₹5,271.902
Dec ’23₹1,736.95
₹1,664.67
-4.2%
18.5%₹2,100.00₹1,422.00₹5,358.603
Nov ’23₹1,482.80
₹1,420.00
-4.2%
21.9%₹1,800.00₹1,038.00₹3,850.853

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

IOL Chemicals and Pharmaceuticals

₹20.5b

Manufactures and sells pharmaceutical and chemical products in India and internationally.

IOLCP

₹348.90

7D

-11.3%

1Y

-16.9%

Solara Active Pharma Sciences

₹35.8b

Manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India, Asia Pacific, Europe, North America, South America, and internationally.

SOLARAPP

₹458.00

7D

-3.8%

1Y

n/a

Caplin Point Laboratories

₹150.9b

Engages in the development, production, marketing, and export of generic pharmaceutical formulations and branded products in India.

CAPLIPOINT

₹1,988.75

7D

-1.2%

1Y

56.6%